is a seasoned executive with 39 years of extensive experience in business management and
consulting in a diverse set of industries spanning consumer products, health care, consumer electronics, major
appliances and housing. Mr. Shad began his career as a territory salesman with Procter and Gamble in 1979,
rising to the head of North American Market Strategy in 2000. He was appointed Global Chief Customer Officer
for Novartis' Consumer Health Division in 2003; he joined LG USA first as Global Chief Go-to-Market Officer in
2008 and was appointed President and CEO in 2009. Mr. Shad later became Viking’s Chief Revenue Officer,
prior to the sale of the company in 2012, and in 2013 he became President of C3 Design, a small start-up in the
housing sector. He is currently Principal of Renaissance Growth Consultants.
Dev Nidhi, is a seasoned technology entrepreneur who has over 20 years of experience in the
IT services industry with a specialisation in Sales and Resource Management. He has built businesses
from ground up and has successfully executed multiple acquisitions, mergers and corporate investments.
He has managed the sales function by working closely with various Fortune 500 customers in the US and
India to sell software solutions, support and staff augmentation related services.
He has successfully prospected and sold IT related service offerings to Bank of America, Pacific Stock exchange, Dresdner
RCM, Wells Fargo, Union Bank of California and Bristol Myers Squibb.
Dev Nidhi co- founded Ivega Corporation in 1997, an international niche IT consulting company with special focus on financial
services. Following this, he founded SaintLife Bio-pharma Pvt. Ltd., which was acquired by a Nasdaq
listed company. Dev Nidhi has a bachelor’s degree in electrical engineering from University of Bangalore
and has also attended a Certificate program in Strategic Sales Management at Chicago Business School.
A member of the Board of Directors since February 2018, Mr. Luci brings to Ameri100 extensive executive leadership in public
and private companies and significant experience in business financings and acquisitions, having overseen
over $180 million of equity raise over his career. Mr. Luci currently serves as Co-Founder, Managing
Partner and a director of Acurx Pharmaceuticals, LLC. Mr. Luci received his B.S.B.A. from Bucknell University
and his J.D. from Albany Law School of Union University.
Mr. Luci is admitted to the New York bar and is an inactive Certified Public Accountant registered
Mr. Shawah brings to the Board of Directors of Ameri100 over 20 years of experience in business management and a strong background in accounting and financial reporting. Currently, and from 2005 to 2013, Mr. Shawah serves as a Partner & Vice President of Baldwin Pearson & Co., Inc., a commercial real estate company, focusing on structuring transactions in the commercial and industrial real estate market in Fairfield County, Connecticut, as well as financial reporting responsibilities for the company. From March 2014 to April 2017, Mr. Shawah served as the Chief Accounting Officer and Treasurer of Dipexium Pharmaceuticals, Inc., a NASDAQ listed biopharmaceutical company. From 1997 to 2005, he served as Sales and Financial Engineer for CC1 Inc., a private New Hampshire firm that designed and manufactured camera-based technical equipment for the printing industry. Prior to 1997, Mr. Shawah held financial management positions at Victorinox/Swiss Army Brands and Grace Cocoa, a division of W.R. Grace. Mr. Shawah is a certified public accountant in the Commonwealth of Pennsylvania (inactive) and spent the first five years of his career in the audit division of Arthur Andersen LLP. Mr. Shawah received his Bachelor’s Degree in Business Administration from Bucknell University
V. Balakrishnan, also known as “Bala”, is the Founder & Chairman of Exfinity Venture Partners,
a Venture Capital Fund focused on investing in the Deep Technology start-up companies. Bala plays an
active role in the start-up ecosystem in India mentoring and investing in several companies.
Mr. Balakrishnan has more than 30 years of experience in strategy, finance, and mergers and acquisitions. He served as the
Chief Financial Officer of Infosys Ltd from 2006 to 2012 and as Secretary and Senior Vice President-Finance
of Infosys Ltd., from 2001 to 2006. Mr. Balakrishnan served as Chairman of the Board at Infosys BPO
Limited and Chairman of Infosys Lodestone. He also served as a full-time board member of Infosys Ltd.
from 2011 to 2013.
Mr. Balakrishnan was the recipient of the "Best CFO" award from CNBC and Finance Asia. His educational background includes
a bachelor of science degree from the University of Madras and he is an Associate Member of the Institute
of Chartered Accountants of India, Institute of Cost and Works Accountants of India and Institute of
Company Secretaries of India. Mr. Balakrishnan serves as the Chairman of MicroGraam which is a peer-to-peer
lending platform that empowers rural entrepreneurs. He is also the trustee of Akshaya Patra Foundation,
a non-governmental organization which provides midday meals to millions of children across India.
Dimitrios Angelis, has served as the Chief Executive Officer of OTI America Inc., the U.S.-based
subsidiary of On Track Innovations Ltd. (NASDAQ:OTIV) (“On Track Innovations”), a pioneer of cashless
payment technology, since December 2013. Mr. Angelis has served as a director of On Track Innovations
since December 2012, and served as its Chairman from April 2013 until February 2015. From October 2012
until December 2013, he has served as the General Counsel of Wockhardt Inc., a biologics and pharmaceutical
company. From October 2008 to October 2012, Mr. Angelis was a senior counsel at Dr. Reddy’s Laboratories,
Ltd. (NYSE:RDY), a publicly traded pharmaceutical company, and during 2008 he was the Chief Legal Officer
and Corporate Secretary of Osteotech, Inc. (formerly NASDAQ:OSTE), a medical device company, with responsibility
for managing the patent portfolio of approximately 42 patents.
Prior to that, in addition to working with McKinsey & Company, Merrill Lynch and the Japanese government, Mr. Angelis has
worked in the pharmaceutical industry in various corporate, strategic and legal roles. He began his
legal career as a transactional associate with law firm Mayer Brown. Mr. Angelis holds a B.A. in Philosophy
and English from Boston College, an M.A. in Behavioural Science from California State University and
Juris Doctor from New York University School of Law.